Wallace Weitz
Weitz Value Fund
Wallace Weitz Laboratory Corp of America Holdings stake
total: 53
Weitz Value Fund LH trades
- Total transactions:
- 14
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 11
- Held since:
- 2019 Q3
- Held for:
- 22 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q1 report, Wallace Weitz doesn't hold any Laboratory Corp of America Holdings (LH) shares. To date, the estimated cost basis is nearly $169.38 for "buy" trades and estimated average "sell" price is $216.96. Weitz Value Fund first purchased LH in 2019 Q3, initially acquiring 205,000 shares. Since the initial investment in Laboratory Corp of America Holdings (LH), Weitz Value Fund has made 13 more transactions.
When did Wallace Weitz sell Laboratory Corp of America Holdings (LH)?
Wallace Weitz sold off the entire Laboratory Corp of America Holdings (LH) position in 2025 Q1.
When did Wallace Weitz buy Laboratory Corp of America Holdings (LH)?
Wallace Weitz first invested in Laboratory Corp of America Holdings (LH) in 2019 Q3 at the reported quarter-end price of $168.00 per share.
What's the cost basis of Weitz Value Fund's LH stake?
The estimated cost basis for Laboratory Corp of America Holdings (LH) stake is around $169.38 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $169.38
- Weighted AVG sell price:
- $216.96
Wallace Weitz's historical trades in Laboratory Corp of America Holdings
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$229.32
|
|
-100% (-75,000)
|
-1.86%
|
|
2024 Q2
|
1.72%
|
75,000
|
$203.51
|
$15,263,250
|
-16.67% (-15,000)
|
-0.32%
|
|
2023 Q4
|
2.31%
|
90,000
|
$227.29
|
$20,456,100
|
-10.00% (-10,000)
|
-0.27%
|
|
2023 Q1
|
2.95%
|
100,000
|
$229.42
|
$22,942,000
|
-4.76% (-5,000)
|
-0.15%
|
|
2022 Q4
|
3.33%
|
105,000
|
$235.48
|
$24,725,400
|
-2.33% (-2,500)
|
-0.08%
|
|
2022 Q3
|
3.09%
|
107,500
|
$204.81
|
$22,017,075
|
-6.52% (-7,500)
|
-0.2%
|
|
2022 Q2
|
3.48%
|
115,000
|
$234.36
|
$26,951,400
|
-8.00% (-10,000)
|
-0.25%
|
|
2021 Q2
|
3.51%
|
125,000
|
$275.85
|
$34,481,250
|
-16.67% (-25,000)
|
-0.74%
|
|
2021 Q1
|
4.12%
|
150,000
|
$255.03
|
$38,254,500
|
-9.09% (-15,000)
|
-0.44%
|
|
2020 Q3
|
3.82%
|
$188.27
|
+10.00% (+15,000)
|
|||
|
2020 Q2
|
3.26%
|
$166.11
|
-20.00% (-37,500)
|
|||
|
2020 Q1
|
3.59%
|
$126.39
|
-3.85% (-7,500)
|
|||
|
2019 Q4
|
3.89%
|
$169.17
|
-4.88% (-10,000)
|
|||
|
2019 Q3
|
4.21%
|
$168.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.